166 related articles for article (PubMed ID: 17934850)
1. Angiotensin II type 1 receptor antagonist suppress angiogenesis and growth of gastric cancer xenografts.
Huang W; Wu YL; Zhong J; Jiang FX; Tian XL; Yu LF
Dig Dis Sci; 2008 May; 53(5):1206-10. PubMed ID: 17934850
[TBL] [Abstract][Full Text] [Related]
2. Functional expression of the angiotensin II type 1 receptor in human ovarian carcinoma cells and its blockade therapy resulting in suppression of tumor invasion, angiogenesis, and peritoneal dissemination.
Suganuma T; Ino K; Shibata K; Kajiyama H; Nagasaka T; Mizutani S; Kikkawa F
Clin Cancer Res; 2005 Apr; 11(7):2686-94. PubMed ID: 15814650
[TBL] [Abstract][Full Text] [Related]
3. Blockade of an angiotensin type I receptor enhances effects of radiation on tumor growth and tumor-associated angiogenesis by reducing vascular endothelial growth factor expression.
Ohnuma Y; Toda M; Fujita M; Hosono K; Suzuki T; Ogawa Y; Amano H; Kitasato H; Hayakawa K; Majima M
Biomed Pharmacother; 2009 Feb; 63(2):136-45. PubMed ID: 18691848
[TBL] [Abstract][Full Text] [Related]
4. Angiotensin II type 1 receptor antagonist candesartan as an angiogenic inhibitor in a xenograft model of bladder cancer.
Kosugi M; Miyajima A; Kikuchi E; Horiguchi Y; Murai M
Clin Cancer Res; 2006 May; 12(9):2888-93. PubMed ID: 16675585
[TBL] [Abstract][Full Text] [Related]
5. Candesartan attenuates angiogenesis in hepatocellular carcinoma via downregulating AT1R/VEGF pathway.
Fan F; Tian C; Tao L; Wu H; Liu Z; Shen C; Jiang G; Lu Y
Biomed Pharmacother; 2016 Oct; 83():704-711. PubMed ID: 27470571
[TBL] [Abstract][Full Text] [Related]
6. Altered efficacy of AT1R-targeted treatment after spontaneous cancer cell-AT1R upregulation.
Ager EI; Wen SW; Chan J; Chong WW; Neo JH; Christophi C
BMC Cancer; 2011 Jun; 11():274. PubMed ID: 21703011
[TBL] [Abstract][Full Text] [Related]
7. Angiotensin II promotes the progression of human gastric cancer.
Huang MM; Guo AB; Sun JF; Chen XL; Yin ZY
Mol Med Rep; 2014 Mar; 9(3):1056-60. PubMed ID: 24424956
[TBL] [Abstract][Full Text] [Related]
8. Effect of angiotensin II type 1 receptor antagonist on tumor growth and angiogenesis in a xenograft model of human bladder cancer.
Kosugi M; Miyajima A; Kikuchi E; Kosaka T; Horiguchi Y; Murai M
Hum Cell; 2007 Feb; 20(1):1-9. PubMed ID: 17506771
[TBL] [Abstract][Full Text] [Related]
9. Angiotensin type 1a receptor signaling-dependent induction of vascular endothelial growth factor in stroma is relevant to tumor-associated angiogenesis and tumor growth.
Fujita M; Hayashi I; Yamashina S; Fukamizu A; Itoman M; Majima M
Carcinogenesis; 2005 Feb; 26(2):271-9. PubMed ID: 15637093
[TBL] [Abstract][Full Text] [Related]
10. Roles for host and tumor angiotensin II type 1 receptor in tumor growth and tumor-associated angiogenesis.
Imai N; Hashimoto T; Kihara M; Yoshida S; Kawana I; Yazawa T; Kitamura H; Umemura S
Lab Invest; 2007 Feb; 87(2):189-98. PubMed ID: 17318197
[TBL] [Abstract][Full Text] [Related]
11. Angiotensin II receptor type 1 blockers suppress the cell proliferation effects of angiotensin II in breast cancer cells by inhibiting AT1R signaling.
Du N; Feng J; Hu LJ; Sun X; Sun HB; Zhao Y; Yang YP; Ren H
Oncol Rep; 2012 Jun; 27(6):1893-903. PubMed ID: 22426690
[TBL] [Abstract][Full Text] [Related]
12. [Effects of angiotensin converting enzyme inhibitors and angiotensin II receptor blockers on angiogenesis of gastric cancer in a nude mouse model].
Wang L; Cai SR; Zhang CH; He YL; Zhan WH; Wu H; Peng JJ
Zhonghua Wei Chang Wai Ke Za Zhi; 2008 Nov; 11(6):565-8. PubMed ID: 19031137
[TBL] [Abstract][Full Text] [Related]
13. Angiotensin II type 1 receptor antagonists inhibit cell proliferation and angiogenesis in breast cancer.
Chen X; Meng Q; Zhao Y; Liu M; Li D; Yang Y; Sun L; Sui G; Cai L; Dong X
Cancer Lett; 2013 Jan; 328(2):318-24. PubMed ID: 23092556
[TBL] [Abstract][Full Text] [Related]
14. A chitosan-graft-PEI-candesartan conjugate for targeted co-delivery of drug and gene in anti-angiogenesis cancer therapy.
Bao X; Wang W; Wang C; Wang Y; Zhou J; Ding Y; Wang X; Jin Y
Biomaterials; 2014 Sep; 35(29):8450-66. PubMed ID: 24997481
[TBL] [Abstract][Full Text] [Related]
15. Angiotensin II type 1 receptor antagonist as an angiogenic inhibitor in prostate cancer.
Kosaka T; Miyajima A; Takayama E; Kikuchi E; Nakashima J; Ohigashi T; Asano T; Sakamoto M; Okita H; Murai M; Hayakawa M
Prostate; 2007 Jan; 67(1):41-9. PubMed ID: 17044086
[TBL] [Abstract][Full Text] [Related]
16. Local angiotensin II-generation in human gastric cancer: correlation with tumor progression through the activation of ERK1/2, NF-kappaB and survivin.
Kinoshita J; Fushida S; Harada S; Yagi Y; Fujita H; Kinami S; Ninomiya I; Fujimura T; Kayahara M; Yashiro M; Hirakawa K; Ohta T
Int J Oncol; 2009 Jun; 34(6):1573-82. PubMed ID: 19424575
[TBL] [Abstract][Full Text] [Related]
17. Candesartan, an angiotensin II type 1 receptor antagonist, inhibits pathological retinal neovascularization by downregulating VEGF receptor-2 expression.
Nakamura S; Tsuruma K; Shimazawa M; Hara H
Eur J Pharmacol; 2012 Jun; 685(1-3):8-14. PubMed ID: 22543084
[TBL] [Abstract][Full Text] [Related]
18. Blockade of angiotensin AT1a receptor signaling reduces tumor growth, angiogenesis, and metastasis.
Fujita M; Hayashi I; Yamashina S; Itoman M; Majima M
Biochem Biophys Res Commun; 2002 Jun; 294(2):441-7. PubMed ID: 12051731
[TBL] [Abstract][Full Text] [Related]
19. Effects of AT1 receptor antagonist and spironolactone on cardiac expression of ET-1 mRNA in SHR-SP/Izm.
Naruse M; Tanabe A; Hara Y; Takagi S; Imaki T; Takano K
J Cardiovasc Pharmacol; 2004 Nov; 44 Suppl 1():S1-3. PubMed ID: 15838251
[TBL] [Abstract][Full Text] [Related]
20. Regulation of monocyte chemoattractant protein-1 through angiotensin II type 1 receptor in prostate cancer.
Shirotake S; Miyajima A; Kosaka T; Tanaka N; Kikuchi E; Mikami S; Okada Y; Oya M
Am J Pathol; 2012 Mar; 180(3):1008-1016. PubMed ID: 22226738
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
